Future Arca BioPharma ops ‘highly dependent’ on Oruka merger
WESTMINSTER — The future of Arca Biopharma Inc. (Nasdaq: ABIO) is “highly dependent” on the successful consummation of its merger with Oruka Therapeutics Inc., the Westminster drug developer said in a regulatory disclosure, and if the deal fails, Arca may …